Scarica l'app Stockscreener
4.49
2.60%
-0.12
Dopo l'orario di chiusura:
4.46
-0.03
-0.67%
Precedente Chiudi:
$4.61
Aprire:
$4.63
Volume 24 ore:
5.04M
Relative Volume:
1.78
Capitalizzazione di mercato:
$1.23B
Reddito:
$6.31M
Utile/perdita netta:
$-99.93M
Rapporto P/E:
-12.67
EPS:
-0.3544
Flusso di cassa netto:
$-85.14M
1 W Prestazione:
-1.75%
1M Prestazione:
-1.32%
6M Prestazione:
+46.25%
1 anno Prestazione:
+161.05%
Intervallo 1D:
$4.37
$4.715
Intervallo di 1 settimana:
$4.345
$4.7692
Portata 52W:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.49 | 1.23B | 6.31M | -99.93M | -85.14M | -0.3544 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Gene therapy biotech Taysha plans March 19 webcast on 2025 financial results - Stock Titan
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - MSN
Jefferies Financial Group Inc. Sells 8,157,091 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Aug Catalysts: How cyclical is Taysha Gene Therapies Incs revenue streamDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Reactions: What hedge funds are buying Taysha Gene Therapies IncTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Decliners Report: Is Taysha Gene Therapies Inc stock good for income investors2025 Winners & Losers & Weekly Top Performers Watchlists - baoquankhu1.vn
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Grants Stock Units and Options to N - GuruFocus
Taysha Gene Therapies announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Highs Report: Is Taysha Gene Therapies Inc attractive for institutional investorsTrade Entry Summary & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Aug Update: Will Taysha Gene Therapies Inc benefit from AI trendsJuly 2025 Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
TSHA SEC FilingsTaysha Gene Therapies, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TSHA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Taysha Gene faces earnings test as Rett trial advances By Investing.com - Investing.com Nigeria
Taysha Gene faces earnings test as Rett trial advances - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC - MarketBeat
TSHA: Needham Reiterates Buy Rating with Price Target Maintained - GuruFocus
TSHA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Taysha Gene Therapies, Inc. (TSHA): Analyst Ratings Signal Potential 140% Upside In Biotech Stock - DirectorsTalk Interviews
Insider sale activity at Taysha Gene Therapies (NASDAQ: TSHA) - Stock Titan
TSHA Should I Buy - Intellectia AI
What is the next catalyst for Taysha Gene Therapies Inc.Long Setup & Precise Buy Zone Identification - mfd.ru
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Taysha Gene Therapies Inc. benefit from AI trendsTrade Entry Summary & Detailed Earnings Play Alerts - mfd.ru
How liquid is Taysha Gene Therapies Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Alert System - mfd.ru
RTW INVESTMENTS, LP Reduces Stake in Taysha Gene Therapies Inc - GuruFocus
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a 129.65% Potential Upside - DirectorsTalk Interviews
Needham Reiterates Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
GSA Capital Partners LLP Increases Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (TSHA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Rate Cut: What is the next catalyst for Taysha Gene Therapies IncEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Commit To Buy Taysha Gene Therapies At $2.50, Earn 16.8% Annualized Using Options - Nasdaq
Portfolio Recap: How does NBBK perform in inflationary periodsJuly 2025 Chart Watch & Consistent Return Investment Signals - baoquankhu1.vn
TSHA PE Ratio & Valuation, Is TSHA Overvalued - Intellectia AI
Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Analyst Consensus Reveals 136.56% Potential Upside - DirectorsTalk Interviews
Does Taysha Gene Therapies Inc. have declining or rising EPSQuarterly Earnings Summary & Fast Entry Momentum Alerts - mfd.ru
Here’s what analysts are saying about Taysha Gene Therapies (TSHA) - MSN
Can Taysha Gene Therapies Inc. outperform under higher oil pricesGDP Growth & Weekly Return Optimization Plans - mfd.ru
Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Tybourne Capital Management HK Ltd. - MarketBeat
Is Taysha Gene Therapies Inc undervalued by DCF analysisJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Retail Trends: What is the next catalyst for Taysha Gene Therapies IncPortfolio Gains Summary & High Accuracy Buy Signal Tips - baoquankhu1.vn
Taysha Gene Therapies (TSHA) Awards Restricted Stock Units to Ne - GuruFocus
Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative? - Yahoo Finance
Taysha Gene Therapies, Inc. (TSHA) gains Wells Fargo’s support on Rett syndrome program progress - MSN
Taysha’s REVEAL Trial Progress Puts Rett Gene Therapy And Valuation In Focus - Sahm
Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds - Citeline News & Insights
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress - Finviz
Institution Moves: Does Taysha Gene Therapies Inc have strong fundamentals2025 Retail Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):